Hepatoid adenocarcinoma of the colon: What should we target?

Alessandro Cappetta, Francesca Bergamo, Claudia Mescoli, Sara Lonardi, Massimo Rugge, Vittorina Zagonel

Research output: Contribution to journalArticle

Abstract

Hepatoid adenocarcinoma is a rare extra hepatic neoplasm that displays morphological and phenotypic features similar to those of hepatocellular carcinoma. We report a case of a 75-year-old woman, presenting with abdominal pain and complaints of weakness and lost of appetite, who was found to have a mass on her right colon. She underwent right hemicolectomy for a pT3N2M0, stage IIIC colon cancer. The tumor phenotype and immunophenotype, as documented by alpha-fetoprotein immunoreaction positivity, were consistent with adenocarcinoma of hepatoid origin. The patient received FOLFOX-4 regimen as adjuvant treatment, relapsed after six cycles, then was switched to FOLFIRI regimen plus Bevacizumab and progressed after only four cycles. She died 1 month later, eight months after the diagnosis. The lack of any clinical benefit despite an aggressive and multimodal therapeutic strategy, raises a question about what should be targeted when we face this rare disease associated with a very poor prognosis.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalPathology and Oncology Research
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2012

Keywords

  • Alpha-fetoprotein
  • Colon cancer
  • FOLFIRI
  • FOLFOX
  • Hepatocellular carcinoma
  • Hepatoid adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Hepatoid adenocarcinoma of the colon: What should we target?'. Together they form a unique fingerprint.

  • Cite this